Background: Second-generation antipsychotic drugs (SGAs) are increasingly administered to achieve weight gain in anorexia nervosa. In this meta-analysis, we aimed to determine if any evidence for this treatment option can be derived from randomized controlled trials (RCTs). Methods: Based on the ‘World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for the Pharmacological Treatment of Eating Disorders', a systematic update literature search was applied to identify all RCTs investigating the efficacy, acceptability, and tolerability of SGAs in anorexia nervosa in comparison to placebo/no treatment. The primary outcome was weight gain measured by mean change in body mass index (BMI). Secondary outcomes were mean changes in Yale-Brown-Cornell Eating Disorders Scale (YBC-EDS) total score and Eating Disorders Inventory (EDI) total score and premature discontinuation of treatment. Employing a random-effects model standardized mean differences based on Hedges's g and Mantel-Haenszel risk ratios were calculated. Results: Seven RCTs (n = 201) investigating olanzapine (N = 4), quetiapine (N = 2), and risperidone (N = 1) were included. We found no statistically significant between-group differences for mean BMI change when pooling the SGAs (N = 7, n = 161; Hedges's g = 0.13, 95% CI: -0.17 to 0.43; p = 0.4) and when examining the individual drugs. Furthermore, the SGAs failed to differentiate statistically significantly from placebo/no treatment for all secondary outcomes. Conclusions: Based on the current evidence, pharmacological treatment of anorexia nervosa with SGAs cannot be generally recommended although some individuals or subgroups of patients might benefit from an antipsychotic medication. Further research is required to identify which patients will likely benefit from such a treatment option.

Keywords:
Eating disorder, Anorexia nervosa, Second-generation antipsychotics, Meta-analysis
1.
Hudson JI, Hiripi E, Pope HG Jr, Kessler RC: The prevalence and correlates of eating disorders in the national comorbidity survey replication. Biol Psychiatry 2007;61:348-358.
2.
Preti A, Girolamo G, Vilagut G, Alonso J, Graaf R, Bruffaerts R, Demyttenaere K, Pinto-Meza A, Haro JM, Morosini P; ESEMeD-WMH Investigators: The epidemiology of eating disorders in six European countries: results of the ESEMeD-WMH project. J Psychiatr Res 2009;43:1125-1132.
3.
Fichter MM, Quadflieg N, Hedlund S: Twelve-year course and outcome predictors of anorexia nervosa. Int J Eat Disord 2006;39:87-100.
4.
Button EJ, Chadalavada B, Palmer RL: Mortality and predictors of death in a cohort of patients presenting to an eating disorders service. Int J Eat Disord 2010;43:387-392.
5.
Keel PK, Dorer DJ, Eddy KT, Franko D, Charatan DL, Herzog DB: Predictors of mortality in eating disorders. Arch Gen Psychiatry 2003;60:179-183.
6.
Rosling AM, Sparen P, Norring C, von Knorring AL: Mortality of eating disorders: a follow-up study of treatment in a specialist unit 1974-2000. Int J Eat Disord 2011;44:304-310.
7.
Signorini A, De Filippo E, Panico S, De Caprio C, Pasanisi F, Contaldo F: Long-term mortality in anorexia nervosa: a report after an 8-year follow-up and a review of the most recent literature. Eur J Clin Nutr 2007;61:119-122.
8.
Treasure J, Claudino AM, Zucker N: Eating disorders. Lancet 2010;375:583-593.
9.
National Clinical Practice Guideline: Eating Disorders: Core Interventions in the Treatment and Management of Anorexia Nervosa, Bulimia Nervosa, and Related Eating Disorders. London, National Institute for Clinical Excellence, 2004.
10.
American Psychiatric Association: Practice Guideline for the Treatment of Patients with Eating Disorders, ed 3. Arlington, American Psychiatric Association, 2006.
11.
Royal Australian and New Zealand College of Psychiatrists Clinical Practice (RANZCP) Guidelines Team for Anorexia Nervosa: Australian and New Zealand clinical practice guidelines for the treatment of anorexia nervosa. Aust NZ J Psychiatry 2004;38:659-670.
12.
Hartmann A, Weber S, Herpertz S, Zeeck A; German Treatment Guideline Group for Anorexia Nervosa: Psychological treatment for anorexia nervosa: a meta-analysis of standardized mean change. Psychother Psychosom 2011;80:216-226.
13.
Dalle Grave R, Calugi S, Conti M, Doll H, Fairburn CG: Inpatient cognitive behaviour therapy for anorexia nervosa: a randomized controlled trial. Psychother Psychosom 2013;82:390-398.
14.
Fazeli PK, Calder GL, Miller KK, Misra M, Lawson EA, Meenaghan E, Lee H, Herzog D, Klibanski A: Psychotropic medication use in anorexia nervosa between 1997 and 2009. Int J Eat Disord 2012;45:970-976.
15.
Hasan A, Falkai P, Wobrock T, Lieberman J, Glenthoj B, Gattaz WF, Thibaut F, Möller HJ: World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, part 2. World J Biol Psychiatry 2013;14:2-44.
16.
Bauer M, Pfennig A, Severus E, Whybrow PC, Angst J, Möller HJ: World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of unipolar depressive disorders, part 1: update 2013. World J Biol Psychiatry 2013;14:334-385.
17.
Kaye W: Neurobiology of anorexia and bulimia nervosa. Physiol Behav 2008;94:121-135.
18.
Kaye WH, Wierenga CE, Bailer UF, Simmons AN, Wagner A, Bischoff-Grethe A: Does a shared neurobiology for foods and drugs of abuse contribute to extremes of food ingestion in anorexia and bulimia nervosa? Biol Psychiatry 2013;73:836-842.
19.
Phillipou A, Rossell SL, Castle DJ: The neurobiology of anorexia nervosa: a systematic review. Aust NZ J Psychiatry 2014;48:128-152.
20.
Aigner M, Treasure J, Kaye W, Kasper S: World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the pharmacological treatment of eating disorders. World J Biol Psychiatry 2011;12:400-443.
21.
Mazure CM, Halmi KA, Sunday SR, Romano SJ, Einhorn AM: The Yale-Brown-Cornell Eating Disorder Scale: development, use, reliability and validity. J Psychiatr Res 1994;28:425-445.
22.
Garner DM: Eating Disorder Inventory-2: Professional Manual. Odessa, Psychological Assessment Resources, 1991.
23.
DerSimonian R, Laird N: Meta-analysis in clinical trials. Control Clin Trials 1986;7:177-188.
24.
Egger M, Davey S, Schneider M, Minder C: Bias in meta-analysis detected by a simple, graphical test. BMJ 1997;315:629-634.
25.
Borenstein M, Hedges L, Higgins J, Rothstein H: Comprehensive Meta-Analysis, version 2. Englewood, Biostat, 2006.
26.
Cochrane Collaboration: Software Review Manager (RevMan), version 5.1.4. Oxford, Cochrane Collaboration, 2011.
27.
Higgins J, Green S: Cochrane Handbook for Systematic Reviews of Interventions, version 5.0.1, updated online March 2011. Chichester, Wiley & Sons, 2011.
28.
Brambilla F, Garcia CS, Fassino S, Daga GA, Favaro A, Santonastaso P, Ramaciotti C, Bondi E, Mellado C, Borriello R, Monteleone P: Olanzapine therapy in anorexia nervosa: psychobiological effects. Int Clin Psychopharmacol 2007;22:197-204.
29.
Bissada H, Tasca GA, Barber AM, Bradwejn J: Olanzapine in the treatment of low body weight and obsessive thinking in women with anorexia nervosa: a randomized, double-blind, placebo-controlled trial. Am J Psychiatry 2008;165:1281-1288.
30.
Court A, Mulder C, Kerr M, Yuen HP, Boasman M, Goldstone S, Fleming J, Weigall S, Derham H, Huang C, McGorry P, Berger G: Investigating the effectiveness, safety and tolerability of quetiapine in the treatment of anorexia nervosa in young people: a pilot study. J Psychiatr Res 2010;44:1027-1034.
31.
Attia E, Kaplan AS, Walsh BT, Gershkovich M, Yilmaz Z, Musante D, Wang Y: Olanzapine versus placebo for out-patients with anorexia nervosa. Psychol Med 2011;41:2177-2182.
32.
Hagman J, Gralla J, Sigel E, Ellert S, Dodge M, Gardner R, O'Lonergan T, Frank G, Wamboldt MZ: A double-blind, placebo-controlled study of risperidone for the treatment of adolescents and young adults with anorexia nervosa: a pilot study. J Am Acad Child Adolesc Psychiatry 2011;50:915-924.
33.
Kafantaris V, Leigh E, Hertz S, Berest A, Schebendach J, Sterling WM, Saito E, Sunday S, Higdon C, Golden NH, Malhotra AK: A placebo-controlled pilot study of adjunctive olanzapine for adolescents with anorexia nervosa. J Child Adolesc Psychopharmacol 2011;21:207-212.
34.
Powers PS, Klabunde M, Kaye W: Double-blind placebo-controlled trial of quetiapine in anorexia nervosa. Eur Eat Disord Rev 2012;20:331-334.
35.
Cohen J: Statistical Power Analysis for the Behavioural Sciences. New York, Academic Press, 1969.
36.
Fava M, Mischoulon D, Iosifescu D, Witte J, Pencina M, Flynn M, Harper L, Levy M, Rickels K, Pollack M: A double-blind, placebo-controlled study of aripiprazole adjunctive to antidepressant therapy among depressed outpatients with inadequate response to prior antidepressant therapy (ADAPT-A Study). Psychother Psychosom 2012;81:87-97.
37.
Fava GA: Rational use of antidepressant drugs. Psychother Psychosom 2014;83:197-204.
38.
Kishi T, Kafantaris V, Sunday S, Sheridan EM, Correll CU: Are antipsychotics effective for the treatment of anorexia nervosa? Results from a systematic review and meta-analysis. J Cin Psychiatry 2012;73:e757-766.
39.
Lebow J, Sim LA, Erwin PJ, Murad MH: The effect of atypical antipsychotic medications in individuals with anorexia nervosa: a systematic review and meta-analysis. Int J Eat Disord 2013;46:332-339.
40.
Vandereycken W, Pierloot R: Pimozide combined with behavior therapy in the short-term treatment of anorexia nervosa: a double-blind placebo-controlled cross-over study. Acta Psychiatr Scand 1982;66:445-450.
41.
Vandereycken W: Neuroleptics in the short-term treatment of anorexia nervosa: a double-blind placebo-controlled study with sulpiride. Br J Psychiatry 1984;144:288-292.
42.
Jane-wit D, Horwitz RI, Concato J: Variation in results from randomized, controlled trials: stochastic or systematic? J Clin Epidemiol 2010;63:56-63.
© 2015 S. Karger AG, Basel
2015
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.